Quinupristin/dalfopristin ['Synercid'] is aimed at the treatment of hospitalised patients with serious infections caused by various Gram-positive cocci that have resistance to many existing antibacterial agents. Of special interest is the activity of quinupristin/dalfopristin against strains ofEnterococcus faeciumwith resistance to vancomycin (VREF). Such strains are generally resistant to many other commonly used antibacterials and can be a major problem in the seriously ill patient. The compound has been tested extensively in 'compassionate use' trials and its activity was a major topic at the 5th International Congress on Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones [Seville, Spain; January 2000].